comparemela.com
Home
Live Updates
Immix Biopharma Awarded European Union Orphan Drug Designati
Immix Biopharma Awarded European Union Orphan Drug Designati
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
European Orphan Drug Designation qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for: EU protocol...
Related Keywords
Gabriel Morris ,
Mike Moyer ,
Ilya Rachman ,
European Commission ,
Exchange Commission ,
Company Annual Report On Form ,
European Medicines Agency ,
European Union ,
Nasdaq ,
Committee For Orphan Medicinal Products ,
Immix Biopharma Inc ,
Company Contact ,
European Orphan Drug Designation ,
Chief Executive Officer ,
Chief Financial Officer ,
Immix Biopharma ,
Single Day ,
Cellular Therapy ,
Orphan Medicinal ,
Orphan Drug Designation ,
Annual Report ,